PDL BioPharma, Inc. (PDLI) Tops Q3 EPS by 2c
Get Alerts PDLI Hot Sheet
Join SI Premium – FREE
PDL BioPharma, Inc. (NASDAQ: PDLI) reported Q3 EPS of $0.32, $0.02 better than the analyst estimate of $0.30. Revenue for the quarter came in at $85.2 million versus the consensus estimate of $85.03 million.
For earnings history and earnings-related data on PDL BioPharma, Inc. (PDLI) click here.
For earnings history and earnings-related data on PDL BioPharma, Inc. (PDLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kinder Morgan (KMI) Misses Q1 EPS by 1c
- Triumph Financial, Inc. (TFIN) Misses Q1 EPS by 20c
- Liberty Oilfield Services (LBRT) Misses Q1 EPS by 6c, provides outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!